presented by

MyoKardia raises $46M Series B for precision medicine approach to cardiomyopathy

San Francisco┬ástartup MyoKardia just closed a $46 million Series B for its precision medicine approach to genetic heart disease. The startup’s studying the genetic root cause of hypertrophic and dilated cardiomyopathies – defects which result in the┬áthickening or weakening off heart tissues, respectively.┬áThe funding will help advance its lead drug candidate, MYK-461, which is in […]